Bullish indicating open at $55-$60, IPO prices at $37
Eterna Therapeutics Inc., a pharmaceutical company, has announced the scheduling of its 2024 annual meeting of stockholders for September 27, 2024. This date is a significant change from the previous year's meeting, occurring more than 30 days before or after the anniversary of the 2023 annual meeting.
The company, formerly known as Brooklyn ImmunoTherapeutics, Inc., and with a history that includes names such as NTN Buzztime Inc. and NTN Communications Inc., made this announcement on August 16, 2024. Stockholders intending to bring business before the annual meeting or nominate candidates for the board of directors must submit their notice by the close of business on August 29, 2024.
Proposals from stockholders that are to be included in Eterna's proxy statement under Rule 14a-8 of the Securities Exchange Act must also be received by the end of business on August 29.
These submissions must adhere to the company's bylaws, Exchange Act regulations, and other applicable laws. The company's principal executive offices, located at 1035 Cambridge Street, Suite 18A, Cambridge, MA, will be the receiving point for all such notifications and proposals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.